Cargando…
Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use
Evidence is increasing that disturbances in the gut microbiome may play a significant role in the etiology of obesity and type 2 diabetes. The short chain fatty acid butyrate, a major end product of the bacterial fermentation of indigestible carbohydrates, is reputed to have anti‐inflammatory proper...
Autores principales: | van Deuren, Thirza, Blaak, Ellen E., Canfora, Emanuel E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541926/ https://www.ncbi.nlm.nih.gov/pubmed/35856338 http://dx.doi.org/10.1111/obr.13498 |
Ejemplares similares
-
Obesity‐related glomerulopathy: Current approaches and future perspectives
por: Martínez‐Montoro, José Ignacio, et al.
Publicado: (2022) -
Butyrate and hexanoate-enriched triglycerides increase postprandrial systemic butyrate and hexanoate in men with overweight/obesity: A double-blind placebo-controlled randomized crossover trial
por: van Deuren, Thirza, et al.
Publicado: (2023) -
Nutritional strategies to attenuate postprandial glycemic response
por: Pasmans, Kenneth, et al.
Publicado: (2022) -
Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons – a scoping review
por: Bliddal, H, et al.
Publicado: (2014) -
Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies
por: Bell, J A, et al.
Publicado: (2014)